Wockhardt launches $40m manufacturing plant in Dubai
Indian pharmaceutical firm Wockhardt has launched its first manufacturing facility in Dubai’s Jebel Ali Free Zone (Jafza). Costing $40 million, the new site will focus on the manufacture of New Chemical Entities (NCEs) to global markets; in particular, it will produce antibiotics designed to combat “superbugs” in the fight against antimicrobial resistance.
At the launch event, Murtaza Khorakiwala, Managing Director of Wockhardt, remarked: “This antibiotic works on organisms that have built resistance to antibiotics, so in a way, this will satisfy an unmet medical need.”
The facility will cover more than 10,000 square metres and is designed to be self-sufficient in manufacturing operations, product testing and stability, and handling warehousing.
Wockhardt is pursuing regulatory approval for the new site; commercial production is currently expected to start in two years.
The company has another four such products which will be manufactured at the facility. Dr Habil Khorakiwala, Founder Chairman at the company, also added: “With Wockhardt’s commitment to R&D, we have five breakthrough NCEs that have been accorded Qualified Infectious Disease Product (QIDP) status by US FDA. With the new facility in the Middle East, we aim to focus on our commitment in developing medicines that can fight antimicrobial resistance.”
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …